S&P 500   4,002.87 (+1.30%)
DOW   32,560.60 (+0.98%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
S&P 500   4,002.87 (+1.30%)
DOW   32,560.60 (+0.98%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
S&P 500   4,002.87 (+1.30%)
DOW   32,560.60 (+0.98%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
S&P 500   4,002.87 (+1.30%)
DOW   32,560.60 (+0.98%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
NYSE:BMY

Bristol-Myers Squibb - BMY Earnings Date, Estimates & Call Transcripts

$67.51
+0.27 (+0.40%)
(As of 03/21/2023 04:00 PM ET)
Add
Compare
Today's Range
$66.87
$67.81
50-Day Range
$65.71
$74.53
52-Week Range
$65.28
$81.43
Volume
8.04 million shs
Average Volume
8.47 million shs
Market Capitalization
$141.69 billion
P/E Ratio
22.88
Dividend Yield
3.38%
Price Target
$79.69

Earnings Summary

Upcoming
Earnings Date
Apr. 27Confirmed
Actual EPS
(Feb. 2)
$1.82 Beat By $0.11
Consensus EPS
(Feb. 2)
$1.71
Last Year's Q1 EPS
(2/4/2022)
$1.83
Skip Charts & View Estimated and Actual Earnings Data

BMY Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

BMY Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Bristol-Myers Squibb Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20233$1.92$2.02$1.98 
Q2 20233$1.94$2.06$2.00 
Q3 20232$1.90$1.99$1.95 
Q4 20233$1.79$2.02$1.88 
FY 202311$7.55$8.09$7.81 
Q1 20242$2.03$2.03$2.03 
Q2 20242$1.98$2.12$2.05 
Q3 20241$2.03$2.03$2.03 
Q4 20241$1.69$1.69$1.69 
FY 20246$7.73$7.87 $7.80

BMY Earnings Date and Information

Bristol-Myers Squibb last posted its earnings results on February 2nd, 2023. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping analysts' consensus estimates of $1.71 by $0.11. The firm had revenue of $11.41 billion for the quarter, compared to analysts' expectations of $11.20 billion. Its quarterly revenue was down 4.8% compared to the same quarter last year. Bristol-Myers Squibb has generated $2.95 earnings per share over the last year ($2.95 diluted earnings per share) and currently has a price-to-earnings ratio of 22.9. Earnings for Bristol-Myers Squibb are expected to decrease by -1.12% in the coming year, from $8.06 to $7.97 per share. Bristol-Myers Squibb has confirmed that its next quarterly earnings report will be published on Thursday, April 27th, 2023. Bristol-Myers Squibb will be holding an earnings conference call on Thursday, April 27th at 8:00 AM Eastern. Interested parties can register for or listen to the call. or dial in at 647-362-9199 with passcode "3734085".

Bristol-Myers Squibb Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
4/27/2023
(Confirmed)
 $1.99       
2/2/2023Q4 2022$1.71$1.82+$0.11$2.69$11.20 billion$11.41 billion    
10/25/2022Q3 2022$1.83$1.99+$0.16$3.23$11.18 billion$11.22 billion      
7/27/2022Q2 2022$1.79$1.93+$0.14$3.20$11.50 billion$11.89 billion      
4/29/2022Q1 2022$1.92$1.96+$0.04$3.33$11.34 billion$11.65 billion      
2/4/2022Q4 2021$1.83$1.83$2.59$12.00 billion$11.96 billion    
10/26/20219/30/2021$1.92$2.00+$0.08$3.31$11.52 billion$11.62 billion    
7/27/20216/30/2021$1.89$1.93+$0.04$3.39$11.24 billion$11.70 billion      
4/28/20213/31/2021$1.82$1.74($0.08)$2.59$11.19 billion$11.07 billion    
2/3/202112/31/2020$1.42$1.46+$0.04$7.37$10.74 billion$11.07 billion  
11/10/20209/30/2020$1.49$1.63+$0.14$2.44$10.33 billion$10.54 billion    
8/6/20206/30/2020$1.48$1.63+$0.15$3.30$10.04 billion$10.13 billion    
5/7/20203/31/2020$1.49$1.72+$0.23$3.78$10.04 billion$10.78 billion  
2/6/202012/31/2019$0.88$1.22+$0.34$2.99$6.20 billion$7.95 billion  
10/31/2019Q3 2019$2.70$2.99+$0.29$3.18$4.39 billion$4.52 billion  
10/31/2019Q3 2019$1.06$1.17+$0.11$1.51$5.89 billion$6.01 billion    
7/30/2019Q2$2.44$2.61+$0.17$3.06$4.22 billion$4.40 billion  
7/25/20196/30/2019$1.06$1.18+$0.12$1.49$6.10 billion$6.27 billion    
4/25/2019Q1 2019$2.45$2.55+$0.10$2.42$4.01 billion$4.03 billion  
4/25/20193/31/2019$1.09$1.10+$0.01$1.16$5.72 billion$5.92 billion    
1/31/2019Q4$2.32$2.39+$0.07$2.90$3.98 billion$4.04 billion
1/24/2019Q4 2018$0.85$0.94+$0.09$1.15$5.95 billion$5.97 billion
10/25/20189/30/2018$2.02$2.29+$0.27$2.56$3.83 billion$3.89 billion  
10/25/20189/30/2018$0.91$1.09+$0.18$1.02$5.72 billion$5.69 billion  
7/26/2018Q2 2018$2.11$2.16+$0.05$2.29$3.70 billion$3.81 billion  
7/26/2018Q2 2018$0.87$1.01+$0.14$1.79$5.48 billion$5.70 billion  
5/4/2018Q1 2018$1.96$2.05+$0.09$2.12$3.47 billion$3.54 billion
4/26/2018Q1 2018$0.85$0.94+$0.09$0.97$5.25 billion$5.19 billion  
2/5/2018Q4 2017$0.67$0.68+$0.01$2.78$5.35 billion$5.45 billion  
1/25/2018Q4 2017$1.78$1.87+$0.09$3.84$3.46 billion$3.48 billion  
10/26/2017Q3 2017$1.87$1.91+$0.04$2.35$3.42 billion$3.29 billion
10/26/2017Q3 2017$0.77$0.75($0.02)$0.99$5.20 billion$5.25 billion
7/27/20176/30/2017$1.61$1.82+$0.21$2.05$3.23 billion$3.27 billion
7/27/2017Q2 2017$0.73$0.74+$0.01$0.92$5.09 billion$5.14 billion
4/27/2017Q1 2017$1.47$1.68+$0.21$1.90$3.04 billion$2.96 billion
4/27/2017Q1 2017$0.72$0.84+$0.12$0.74$4.75 billion$4.93 billion
1/26/2017Q416$1.59$1.61+$0.02$2.29$3.03 billion$2.98 billion
1/26/2017Q416$0.67$0.63($0.04)$0.73$5.14 billion$5.24 billion
10/27/2016Q316$1.31$1.58+$0.27$2.57$2.84 billion$2.98 billion  
10/27/2016Q316$0.65$0.77+$0.12$0.82$4.76 billion$4.83 billion  
7/28/2016Q216$1.39$1.44+$0.05$1.81$2.70 billion$2.74 billion  
7/28/2016Q216$0.67$0.69+$0.02$0.69$4.60 billion$4.90 billion  
4/28/2016Q116$1.29$1.32+$0.03$1.37$2.59 billion$2.51 billion  
4/28/2016Q116$0.65$0.74+$0.09$0.77$4.19 billion$4.39 billion  
1/28/2016Q415$1.22$1.18($0.04)$1.31$2.54 billion$2.54 billion  
1/28/2016Q415$0.28$0.38+$0.10$0.84$4.07 billion$4.29 billion  
11/5/2015Q315$1.09$1.23+$0.14$2.28$2.40 billion$2.33 billion
10/27/2015Q315$0.35$0.39+$0.04$0.36$3.83 billion$4.07 billion  
7/23/2015Q215$1.08$1.23+$0.15$1.73$2.24 billion$2.28 billion  
7/23/2015Q215$0.36$0.53+$0.17$1.14$3.68 billion$4.16 billion  
4/30/2015Q115$0.93$0.95+$0.02$1.04$2.11 billion$2.08 billion
4/28/2015Q115$0.50$0.71+$0.21$0.71$3.80 billion$4.04 billion
1/29/2015Q414$0.88$0.91+$0.03$1.08$2.08 billion$2.09 billion
1/27/2015Q414$0.40$0.46+$0.06$0.91$4.02 billion$4.26 billion
10/24/2014Q314$0.42$0.45+$0.03$0.47$3.80 billion$3.92 billion  
10/23/2014Q314$0.82$0.97+$0.15$1.15$1.96 billion$1.96 billion  
7/24/2014Q214$0.77$0.80+$0.03$0.88$1.85 billion$1.87 billion
7/24/2014Q214$0.44$0.48+$0.04$0.76$3.85 billion$3.89 billion  
4/29/2014Q114$0.43$0.46+$0.03$0.36$3.89 billion$3.81 billion  
4/24/2014Q114$1.65$1.67+$0.02$1.13$1.77 billion$1.71 billion  
1/30/2014Q4 2013$0.70$0.67($0.03)$1.09$1.72 billion$1.76 billion  
1/24/2014Q4 2013$0.43$0.51+$0.08$0.58$4.30 billion$4.44 billion  
10/24/2013Q3 2013$0.69$0.70+$0.01$0.96$1.64 billion$1.67 billion
10/23/2013Q3 2013$0.44$0.46+$0.02$0.50$4.02 billion$4.07 billion  
7/25/2013Q2 2013$0.65$0.70+$0.05$0.84$1.54 billion$1.56 billion  
7/25/2013Q2 2013$0.44$0.44$0.56$4.07 billion$4.05 billion  
4/25/2013Q1 2013$0.62$0.63+$0.01$0.81$1.47 billion$1.43 billion  
4/25/2013Q1 2013$0.41$0.41$0.45$3.88 billion$3.83 billion  
1/24/2013Q4 2012$1.31$1.32+$0.01$1.45 billion$1.42 billion  
1/24/2013Q4 2012$0.42$0.47+$0.05$4.14 billion$4.19 billion  
10/25/2012$1.26$1.29+$0.03  
10/24/2012$0.42$0.41($0.01)  
7/26/2012$1.19$1.22+$0.03
7/25/2012$0.48$0.48
4/26/2012$1.13$1.08($0.05)
4/26/2012$0.64$0.64
1/26/2012$1.06$1.05($0.01)
1/26/2012$0.55$0.53($0.02)
10/27/2011$0.95$1.02+$0.07
10/27/2011$0.58$0.61+$0.03
7/28/2011$0.85$0.89+$0.04
7/28/2011$0.55$0.56+$0.01
4/28/2011$0.80$0.83+$0.03
4/28/2011$0.53$0.58+$0.05
1/27/2011$0.73$0.73
1/27/2011$0.48$0.47($0.01)  
10/28/2010Q3 2010$0.32$0.32$0.34
7/29/2010Q2 2010$0.30$0.30$0.43
4/29/2010Q1 2010$0.28$0.27($0.01)$0.29
1/28/2010Q4 2009$0.29$0.29$0.31
10/22/2009Q3 2009$0.25$0.25$0.27
7/23/2009Q2 2009$0.21$0.20($0.01)$0.25
4/30/2009Q1 2009$0.20$0.16($0.04)$0.15
1/29/2009Q4 2008$0.19$0.19$0.54
10/23/2008Q3 2008$0.18$0.17($0.01)$0.19
7/24/2008Q2 2008$0.16$0.15($0.01)$0.17
5/8/2008Q1 2008$0.16$0.17+$0.01$2.33
1/31/2008Q4 2007$0.15$0.15$0.21












Bristol-Myers Squibb Earnings - Frequently Asked Questions

When is Bristol-Myers Squibb's earnings date?

Bristol-Myers Squibb has confirmed that its next quarterly earnings data will be published on Thursday, April 27th, 2023. Learn more on BMY's earnings history.

Did Bristol-Myers Squibb beat their earnings estimates last quarter?

In the previous quarter, Bristol-Myers Squibb (NYSE:BMY) reported $1.82 earnings per share (EPS) to beat the analysts' consensus estimate of $1.71 by $0.11. Learn more on analysts' earnings estimate vs. BMY's actual earnings.

How can I listen to Bristol-Myers Squibb's earnings conference call?

The conference call for Bristol-Myers Squibb's latest earnings report can be listened to online. Listen to Conference Call

How can I read Bristol-Myers Squibb's conference call transcript?

The conference call transcript for Bristol-Myers Squibb's latest earnings report can be read online. Read Transcript

How much revenue does Bristol-Myers Squibb generate each year?

Bristol-Myers Squibb (NYSE:BMY) has a recorded annual revenue of $46.16 billion.

How much profit does Bristol-Myers Squibb generate each year?

Bristol-Myers Squibb (NYSE:BMY) has a recorded net income of $6.33 billion. BMY has generated $2.95 earnings per share over the last four quarters.

What is Bristol-Myers Squibb's price-to-earnings ratio?

Bristol-Myers Squibb (NYSE:BMY) has a trailing price-to-earnings ratio of 22.88 and a forward price-to-earnings ratio of 8.38. The price/earnings-to-growth ratio is 1.45.

What is Bristol-Myers Squibb's EPS forecast for next year?

Bristol-Myers Squibb's earnings are expected to decrease from $8.06 per share to $7.97 per share in the next year, which is a -1.12% change.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NYSE:BMY) was last updated on 3/21/2023 by MarketBeat.com Staff